HIV-1 infection

Active Ingredient: Etravirine

Indication for Etravirine

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Etravirine, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years of age.

For this indication, competent medicine agencies globally authorize below treatments:

200-400 mg in 2 divided doses daily

Route of admnistration

Oral

Defined daily dose

200 - 400 mg

Dosage regimen

From 100 To 200 mg 2 time(s) per day every day

Detailed description

The recommended dose of etravirine for paediatric patients (6 years to less than 18 years of age and weighing at least 16 kg) is based on body weight (see table below). Etravirine tablet(s) should be taken orally, following a meal.

Recommended dose of etravirine for paediatric patients 6 years to less than 18 years of age:

Body weightDoseTablets
≥16 to <20 kg 100 mg twice dailyfour 25 mg tablets twice daily or one 100 mg tablet twice daily
≥20 to <25 kg 125 mg twice dailyfive 25 mg tablets twice daily or one 100 mg tablet and one 25 mg tablet twice daily
≥25 to <30 kg 150 mg twice dailysix 25 mg tablets twice daily or one 100 mg tablet and two 25 mg tablets twice daily
≥30 kg 200 mg twice dailyeight 25 mg tablets twice daily or two 100 mg tablets twice daily or one 200 mg tablet twice daily

Missed dose

If the patient misses a dose of etravirine within 6 hours of the time it is usually taken, the patient should take it following a meal as soon as possible and then take the next dose at the regularly scheduled time. If a patient misses a dose by more than 6 hours of the time it is usually taken, the patient should not take the missed dose and simply resume the usual dosing schedule.

If a patient vomits within 4 hours of taking the medicine, another dose of etravirine should be taken following a meal as soon as possible. If a patient vomits more than 4 hours after taking the medicine, the patient does not need to take another dose until the next regularly scheduled time.

Dosage considerations

Take after meal.

Active ingredient

Etravirine

Etravirine is an non-nucleoside reverse transcriptase inhibitors (NNRTI) of human immunodeficiency virus type 1 (HIV-1). Etravirine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme’s catalytic site.

Read more about Etravirine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.